Conferences - Results from #20

Viewing 21-40 of 11775 articles

SCS AUA 2024: High Risk NMIBC Treatment: The Case for Bladder Sparing Therapy

SCS AUA 2024: The Top 10 Reasons Why BCG (as a Monotherapy) Will Cease to Exist

SCS AUA 2024: BCG Will Always Be the First Line: Yes

SCS AUA 2024: BCG Shortage – An End in Sight?

SCS AUA 2024: Emerging Treatments for NMIBC

SCS AUA 2024: Clinical Trial Updates for Treatment of Metastatic Prostate Cancer

SCS AUA 2024: Focal Therapy in Prostate Cancer

SCS AUA 2024: Transitioning Men to Watchful Waiting

SCS AUA 2024: Active Surveillance for Low Volume Gleason Grade Group 2 Disease: Con

SCS AUA 2024: Active Surveillance for Intermediate Risk Prostate Cancer

ASTRO 2024: Hyaluronic Acid Rectal Spacer in Locally Recurrent Prostate Cancer with Prior Radiation Receiving SBRT: Feasibility, Safety, and Toxicity

ASTRO 2024: Prostate CAncer integrated Risk Evaluation (P-CARE): A Model to Stratify Risk of Any, Metastatic, and Fatal Prostate Cancer

ASTRO 2024: The Interplay between Acute and Late Toxicity among Patients Receiving Prostate Radiotherapy: A Pooled Analysis of 7 Randomized Trials

ASTRO 2024: Examination of Decipher® Prostate Genomic Classifier in Patients with De Novo Metastatic Disease from a Large Scale Real-World Clinical and Transcriptomic Data Linkage

ASTRO 2024: A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY)

ASTRO 2024: A Digital Pathology MMAI Algorithm is Associated with Pro-Metastatic Genomic Pathways in Oligometastatic Prostate Cancer

ASTRO 2024: Validation of a Digital Pathology-Based MMAI Model in Oligometastatic Castration-Sensitive Prostate Cancer, including Patients from the STOMP and ORIOLE Phase II Randomized Trial

ASTRO 2024: Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer Reversal Protocol

ASTRO 2024: Impact of Hyaluronic Acid Rectal Spacer Quality Score and Fischer-Valuck Spacer Symmetry Score on Rectal Dosimetry and Acute and Late Gastrointestinal Toxicity Outcomes – An Australian Experience

ASTRO 2024: SBRT versus Conventional Fractionation EBRT Boost for Unfavorable Intermediate and High-Risk Prostate Cancer. Early Results of PBS phase II randomized trial

1
2
3
4
5
6
7
8
9
10